Immuneering Corporation (IMRX) financial statements and ratios from SEC XBRL: revenue $3.04M (TTM), net margin -1843.3%, revenue growth 17.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $3.04M |
| Net Margin | -1843.3% |
| Revenue Growth (YoY) | 17.2% |
| EPS Growth (YoY) | -37.7% |
| FCF Growth (YoY) | -17.4% |
| Price / Book | 1.80 |
| Price / Sales | 81.27 |
| FCF Yield | -31.4% |
| Altman Z-Score | 8.70 (safe) |
| Sector P/E (Healthcare) | 21.7 |
IMRX overview · IMRX earnings · IMRX KPIs · IMRX investor relations · IMRX ownership · IMRX peers · IMRX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.